Co-CEO Robert Duggan Buys $1.46 Million in Summit Therapeutics Stock
SMMT is trading near its 52-week low of $13.83 (9.3% above the low).
Summary
Co-CEO Robert W. Duggan purchased $1.46 million of Summit Therapeutics stock on the open market, joining the CFO in recent insider buying after positive drug trial results.
Key Events · Ownership and Investor Activity · SMMT
-
Co-CEO Open Market Purchase
Robert W. Duggan, Co-Chief Executive Officer, Director, and 10% Owner, purchased 100,000 shares for $1,460,000 at $14.60 per share on June 4, 2026.
-
Executive Buying Cluster
This purchase follows a $722,250 open market buy by COO and CFO Manmeet Soni on the same day, indicating a cluster of executive confidence.
-
Post-Positive Drug Data
The insider buying occurs shortly after Summit Therapeutics announced groundbreaking Phase III overall survival data for its lead drug candidate, ivonescimab, on June 1, 2026.
Analysis · SMMT · Life Sciences
Co-CEO Robert W. Duggan's $1.46 million open market purchase, alongside the CFO's recent buy, demonstrates strong insider confidence following the company's positive Phase III ivonescimab data. While the percentage of market cap is small, the absolute dollar value and the cluster of executive buying signal conviction in the company's future prospects.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 29.2% of the 1503 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SMMT was trading at $15.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.5B. The 52-week trading range was $13.83 to $30.98. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.